In 2025, Montefiore Einstein physician-scientists published new clinical research describing, for the first time, the rapid hemodynamic changes observed in their cohort following initiation of sotatercept in patients with pulmonary arterial hypertension (PAH), using remote pulmonary artery pressure monitoring. The findings, published in The Journal of Heart and Lung Transplantation in December 2025, provide early physiologic insight into treatment response shortly after therapy begins, when timely intervention is critical.

In six patients with PAH who were implanted with a pulmonary artery sensor system (CardioMEMS™ HF System) as part of routine care or prior clinical protocols by Sandhya Murthy, MD, Associate Professor of Medicine in the Division of Cardiology at Albert Einstein College of Medicine, Montefiore Einstein researchers documented early hemodynamic changes following initiation of sotatercept through weekly remote transmissions. This approach, the result of collaboration between the Divisions of Cardiology and Pulmonary Medicine, enabled frequent longitudinal tracking of pulmonary artery pressures beyond traditional, episodic assessment, offering early insight into hemodynamic response. For patients with PAH, this type of remote physiologic monitoring may help care teams assess response earlier, potentially reducing reliance on repeated invasive testing and supporting more timely, individualized treatment decisions.

“What stood out in this cohort was how rapidly we observed hemodynamic changes after sotatercept initiation—much earlier than what has been described in prior studies that relied on measurements at baseline and six months,” said Kate Steinberg, MD, of Montefiore Einstein’s Division of Pulmonary and Critical Care Medicine. “This unique approach of combining remote pulmonary artery pressure monitoring allowed us to gain important insight into the potential timeline of drug efficacy and treatment response.”

Pulmonary arterial hypertension is a progressive and debilitating disease characterized by elevated pulmonary vascular resistance, right ventricular strain and eventual right heart failure. Despite advances in therapy over the past several decades, PAH remains incurable and is associated with significant morbidity and mortality. While contemporary treatment strategies have focused largely on pulmonary vasodilation, newer therapies such as sotatercept are designed to target pathways involved in pulmonary vascular remodeling, a central contributor to disease progression.

This research reflects Montefiore Einstein’s broader leadership in pulmonary hypertension care, where our patients have access to the full spectrum of U.S. Food and Drug Administration (FDA)-approved therapies, including newer agents such as sotatercept (Winrevair) and inhaled treprostinil (Yutrepia™). Care is delivered through a multidisciplinary approach that integrates a team of world-renowned specialists in pulmonary medicine and cardiology with state-of-the-art remote physiologic monitoring technologies to support personalized, real-time management.

This remote-first approach allows optimized PAH care to be guided by the most up-to-date physiologic data. It supports ongoing management of pulmonary hypertension for patients who may otherwise face barriers to frequent in-person evaluation, helping ensure that advanced, life-saving therapies can be delivered consistently to the patients we serve.

Montefiore Einstein is ranked in the top 1% of all hospitals in the nation for pulmonology and lung surgery, according to U.S. News & World Report. This study underscores Montefiore Einstein’s continued commitment to innovation and to improving outcomes and quality of life for individuals living with PAH.

Publication:

Nagaraj S, Suhotliv A, Yakkali S, Steinberg K, Jorde UP, Farber HW, Murthy S. Hemodynamic effects of sotatercept administration in pulmonary hypertension - Insights from remote monitoring. J Heart Lung Transplant. 2025;44(12):2008-2011. doi:10.1016/j.healun.2025.07.032